세계의 벤조디아제핀 API 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Benzodiazepine APIs Market - Scope of Report

TMR's report on the global Benzodiazepine APIs Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Benzodiazepine APIs Market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Benzodiazepine APIs Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Benzodiazepine APIs Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Benzodiazepine APIs Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Benzodiazepine APIs Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Benzodiazepine APIs Market.

The report delves into the competitive landscape of the global Benzodiazepine APIs Market. Key players operating in the global Benzodiazepine APIs Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Benzodiazepine APIs Market profiled in this report.

Key Questions Answered in Global Benzodiazepine APIs Market Report:

• What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
• What are the opportunities in the global Benzodiazepine APIs Market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Benzodiazepine APIs Market - Research Objectives and Research Approach

The comprehensive report on the global Benzodiazepine APIs Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Benzodiazepine APIs Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Benzodiazepine APIs.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Benzodiazepine APIs Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Benzodiazepine APIs Market Analysis and Forecast, 2017 - 2031
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Benzodiazepine Application Overview
• 5.2. Regulatory Scenario for Benzodiazepines in China and U.S.
• 5.3. Top 3 Markets for Clonazepam in Europe
• 5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short/Mid/Long Term impact)

6. Global Benzodiazepine APIs Market Analysis and Forecast, by Product

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast, by Product, 2017 - 2031
  • 6.3.1. Alprazolam
  • 6.3.2. Bromazepam
  • 6.3.3. Chlordiazepoxide
  • 6.3.4. Clobazam
  • 6.3.5. Clonazepam
  • 6.3.6. Clorazepate
  • 6.3.7. Diazepam
  • 6.3.8. Lorazepam
  • 6.3.9. Midazolam
  • 6.3.10. Nitrazepam
  • 6.3.11. Oxazepam
  • 6.3.12. Temazepam
  • 6.3.13. Others
• 6.4. Market Attractiveness, by Product

7. Global Benzodiazepine APIs Market Analysis and Forecast, by Time of Action

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast, by Time of Action, 2017 - 2031
  • 7.3.1. Short Acting
  • 7.3.2. Intermediate
  • 7.3.3. Long Acting
• 7.4. Market Attractiveness, by Time of Action

8. Global Benzodiazepine APIs Market Analysis and Forecast, by End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast, by End-user, 2017 - 2031
  • 8.3.1. Pharmaceutical & Biotechnology Industries
  • 8.3.2. CMOs
  • 8.3.3. Others (Research Institutes, etc.)
• 8.4. Market Attractiveness, by End-user

9. Global Benzodiazepine APIs Market Analysis and Forecast, by Region

• 9.1. Key Findings
• 9.2. Market Value Forecast, by Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness, by Country/Region

10. North America Benzodiazepine APIs Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast, by Product, 2017 - 2031
  • 10.2.1. Alprazolam
  • 10.2.2. Bromazepam
  • 10.2.3. Chlordiazepoxide
  • 10.2.4. Clobazam
  • 10.2.5. Clonazepam
  • 10.2.6. Clorazepate
  • 10.2.7. Diazepam
  • 10.2.8. Lorazepam
  • 10.2.9. Midazolam
  • 10.2.10. Nitrazepam
  • 10.2.11. Oxazepam
  • 10.2.12. Temazepam
  • 10.2.13. Others
• 10.3. Market Value Forecast, by Time of Action, 2017 - 2031
  • 10.3.1. Short Acting
  • 10.3.2. Intermediate
  • 10.3.3. Long Acting
• 10.4. Market Value Forecast, by End-user, 2017 - 2031
  • 10.4.1. Pharmaceutical & Biotechnology Industries
  • 10.4.2. CMOs
  • 10.4.3. Others (Research Institutes, etc.)
• 10.5. Market Value Forecast, by Country, 2017 - 2031
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Product
  • 10.6.2. By Time of Action
  • 10.6.3. By End-user
  • 10.6.4. By Country

11. Europe Benzodiazepine APIs Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Product, 2017 - 2031
  • 11.2.1. Alprazolam
  • 11.2.2. Bromazepam
  • 11.2.3. Chlordiazepoxide
  • 11.2.4. Clobazam
  • 11.2.5. Clonazepam
  • 11.2.6. Clorazepate
  • 11.2.7. Diazepam
  • 11.2.8. Lorazepam
  • 11.2.9. Midazolam
  • 11.2.10. Nitrazepam
  • 11.2.11. Oxazepam
  • 11.2.12. Temazepam
  • 11.2.13. Others
• 11.3. Market Value Forecast, by Time of Action, 2017 - 2031
  • 11.3.1. Short Acting
  • 11.3.2. Intermediate
  • 11.3.3. Long Acting
• 11.4. Market Value Forecast, by End-user, 2017 - 2031
  • 11.4.1. Pharmaceutical & Biotechnology Industries
  • 11.4.2. CMOs
  • 11.4.3. Others (Research Institutes, etc.)
• 11.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Product
  • 11.6.2. By Time of Action
  • 11.6.3. By End-user
  • 11.6.4. By Country/Sub-region

12. Asia Pacific Benzodiazepine APIs Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Product, 2017 - 2031
  • 12.2.1. Alprazolam
  • 12.2.2. Bromazepam
  • 12.2.3. Chlordiazepoxide
  • 12.2.4. Clobazam
  • 12.2.5. Clonazepam
  • 12.2.6. Clorazepate
  • 12.2.7. Diazepam
  • 12.2.8. Lorazepam
  • 12.2.9. Midazolam
  • 12.2.10. Nitrazepam
  • 12.2.11. Oxazepam
  • 12.2.12. Temazepam
  • 12.2.13. Others
• 12.3. Market Value Forecast, by Time of Action, 2017 - 2031
  • 12.3.1. Short Acting
  • 12.3.2. Intermediate
  • 12.3.3. Long Acting
• 12.4. Market Value Forecast, by End-user, 2017 - 2031
  • 12.4.1. Pharmaceutical & Biotechnology Industries
  • 12.4.2. CMOs
  • 12.4.3. Others (Research Institutes, etc.)
• 12.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 12.5.1. China
  • 12.5.2. Japan
  • 12.5.3. India
  • 12.5.4. Australia & New Zealand
  • 12.5.5. Rest of APAC
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Product
  • 12.6.2. By Time of Action
  • 12.6.3. By End-user
  • 12.6.4. By Country/Sub-region

13. Latin America Benzodiazepine APIs Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Product, 2017 - 2031
  • 13.2.1. Alprazolam
  • 13.2.2. Bromazepam
  • 13.2.3. Chlordiazepoxide
  • 13.2.4. Clobazam
  • 13.2.5. Clonazepam
  • 13.2.6. Clorazepate
  • 13.2.7. Diazepam
  • 13.2.8. Lorazepam
  • 13.2.9. Midazolam
  • 13.2.10. Nitrazepam
  • 13.2.11. Oxazepam
  • 13.2.12. Temazepam
  • 13.2.13. Others
• 13.3. Market Value Forecast, by Time of Action, 2017 - 2031
  • 13.3.1. Short Acting
  • 13.3.2. Intermediate
  • 13.3.3. Long Acting
• 13.4. Market Value Forecast, by End-user, 2017 - 2031
  • 13.4.1. Pharmaceutical & Biotechnology Industries
  • 13.4.2. CMOs
  • 13.4.3. Others (Research Institutes, etc.)
• 13.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Product
  • 13.6.2. By Time of Action
  • 13.6.3. By End-user
  • 13.6.4. By Country/Sub-region

14. Middle East & Africa Benzodiazepine APIs Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Product, 2017 - 2031
  • 14.2.1. Alprazolam
  • 14.2.2. Bromazepam
  • 14.2.3. Chlordiazepoxide
  • 14.2.4. Clobazam
  • 14.2.5. Clonazepam
  • 14.2.6. Clorazepate
  • 14.2.7. Diazepam
  • 14.2.8. Lorazepam
  • 14.2.9. Midazolam
  • 14.2.10. Nitrazepam
  • 14.2.11. Oxazepam
  • 14.2.12. Temazepam
  • 14.2.13. Others
• 14.3. Market Value Forecast, by Time of Action, 2017 - 2031
  • 14.3.1. Short Acting
  • 14.3.2. Intermediate
  • 14.3.3. Long Acting
• 14.4. Market Value Forecast, by End-user, 2017 - 2031
  • 14.4.1. Pharmaceutical & Biotechnology Industries
  • 14.4.2. CMOs
  • 14.4.3. Others (Research Institutes, etc.)
• 14.5. Market Value Forecast, by Country/Sub-region, 2017 - 2031
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Product
  • 14.6.2. By Time of Action
  • 14.6.3. By End-user
  • 14.6.4. By Country/Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis, by Company (2022)
• 15.3. Company Profiles
  • 15.3.1. Sun Pharmaceutical Industries Ltd.
    • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.1.2. Product Portfolio
    • 15.3.1.3. Financial Overview
    • 15.3.1.4. SWOT Analysis
    • 15.3.1.5. Strategic Overview
  • 15.3.2. Merck KGaA
    • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.2.2. Product Portfolio
    • 15.3.2.3. Financial Overview
    • 15.3.2.4. SWOT Analysis
    • 15.3.2.5. Strategic Overview
  • 15.3.3. LGC GmbH (LGC Science Group Holdings Limited)
    • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.3.2. Product Portfolio
    • 15.3.3.3. Financial Overview
    • 15.3.3.4. SWOT Analysis
    • 15.3.3.5. Strategic Overview
  • 15.3.4. Nortec Quimica S.A.
    • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.4.2. Product Portfolio
    • 15.3.4.3. Financial Overview
    • 15.3.4.4. SWOT Analysis
    • 15.3.4.5. Strategic Overview
  • 15.3.5. Centaur Pharmaceuticals
    • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.5.2. Product Portfolio
    • 15.3.5.3. Financial Overview
    • 15.3.5.4. SWOT Analysis
    • 15.3.5.5. Strategic Overview
  • 15.3.6. Eisai Co., Ltd
    • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.6.2. Product Portfolio
    • 15.3.6.3. Financial Overview
    • 15.3.6.4. SWOT Analysis
    • 15.3.6.5. Strategic Overview
  • 15.3.7. Global Calcium PVT LTD
    • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.7.2. Product Portfolio
    • 15.3.7.3. Financial Overview
    • 15.3.7.4. SWOT Analysis
    • 15.3.7.5. Strategic Overview
  • 15.3.8. Delphis Pharma
    • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.8.2. Product Portfolio
    • 15.3.8.3. Financial Overview
    • 15.3.8.4. SWOT Analysis
    • 15.3.8.5. Strategic Overview
  • 15.3.9. Mylan N.V. (Viatris Inc.)
    • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.9.2. Product Portfolio
    • 15.3.9.3. Financial Overview
    • 15.3.9.4. SWOT Analysis
    • 15.3.9.5. Strategic Overview
  • 15.3.10. Taj Pharmaceuticals Ltd.
    • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.10.2. Product Portfolio
    • 15.3.10.3. Financial Overview
    • 15.3.10.4. SWOT Analysis
    • 15.3.10.5. Strategic Overview